{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:28:42Z","timestamp":1765704522711,"version":"3.44.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T00:00:00Z","timestamp":1407974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UL1RR025005"],"award-info":[{"award-number":["UL1RR025005"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jhep.2014.08.006","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T01:17:22Z","timestamp":1414977442000},"page":"S108-S119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S","title":["Management of acute and chronic HCV infection in persons with HIV coinfection"],"prefix":"10.1016","volume":"61","author":[{"given":"Mark S.","family":"Sulkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.08.006_b0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2012.12.026","article-title":"Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997","volume":"144","author":"van der Helm","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0010","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/cis694","article-title":"Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic","volume":"55","author":"Wandeler","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0015","first-page":"945","article-title":"Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men \u2013 New York City, 2005\u20132010","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhep.2014.08.006_b0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1089\/aid.2011.0289","article-title":"Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients","volume":"28","author":"Laguno","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jhep.2014.08.006_b0025","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e3283471cce","article-title":"The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007","volume":"25","author":"van der Helm","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2014.08.006_b0030","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","article-title":"Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men","volume":"136","author":"van de Laar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","article-title":"Incidence and transmission patterns of acute hepatitis C in the United States, 1982\u20132006","volume":"171","author":"Williams","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS treatment network (NEAT) consensus conference","volume":"25","author":"European, A.T.N.A.H.C.I.C.P.","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2014.08.006_b0045","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0055","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.08.006_b0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0065","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2012.02.012","article-title":"Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals","volume":"142","author":"Naggie","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/0003-4819-158-9-201305070-00604","article-title":"HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study","volume":"158","author":"Kirk","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the united states between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0080","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV","volume":"308","author":"Limketkai","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.08.006_b0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","article-title":"Human immunodeficiency virus-related microbial translocation and progression of hepatitis C","volume":"135","author":"Balagopal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0090","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/hep.27158","article-title":"Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus\/hepatitis C virus coinfected patients","volume":"60","author":"Balagopal","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.006_b0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3851\/IMP2686","article-title":"Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals","volume":"19","author":"Rohrbach","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2014.08.006_b0100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/gut.2009.205971","article-title":"Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy","volume":"59","author":"Rohrbach","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.08.006_b0105","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection","volume":"362","author":"Qurishi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.08.006_b0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/499055","article-title":"Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?","volume":"42","author":"Verma","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0115","unstructured":"Adolescents, P.o.O.I.i.H.I.V.I.A.a., Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America; 2103: R-1-R-17."},{"key":"10.1016\/j.jhep.2014.08.006_b0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.08.006_b0125","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1310\/hct1303-142","article-title":"Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial","volume":"13","author":"Rodriguez-Torres","year":"2012","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jhep.2014.08.006_b0140","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2014.08.006_b0145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2011.05.032","article-title":"Gaps in the achievement of effectiveness of HCV treatment in national VA practice","volume":"56","author":"Kramer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0150","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0155","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0160","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2014.08.006_b0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0170","first-page":"10","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","author":"Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0175","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.08.006_b0525","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60016-7","article-title":"Use of sofosbuvir\/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV","volume":"60","author":"Osinusi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0530","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(14)60065-9","article-title":"Efficacy and safety of the all-oral regimen, MK-5172\/MK-8742 +\/\u2212 ribavirin for 12 weeks in GT1 HCV\/HIV coinfected patients: the C-WORTHY study","volume":"60","author":"Sulkowski","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0535","unstructured":"Rodriguez-Torres M et al. Sofosbuvir and Peginterferon alfa-2a\/Ribavirin forTreatment-Na\u00efve Genotype 1\u20134 HCV Infected Patients who are HIV Coinfected with HIV. ID Week 2013, San Francisco, CA, October 2\u20136, 2013; abstract 714."},{"key":"10.1016\/j.jhep.2014.08.006_b0540","unstructured":"Dieterich, DT et al. Simeprevir (TMC435) plus peginterferon\/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the C212 study. 14th European AIDs Conference (EACS 2013). Brussels, October 16\u201319, 2013; abstract PS9\/5."},{"key":"10.1016\/j.jhep.2014.08.006_b0200","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0205","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2008-11-190231","article-title":"Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression","volume":"113","author":"Hardy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2014.08.006_b0210","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0215","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0220","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.006_b0230","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.08.006_b0235","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.08.006_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0245","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.08.006_b0250","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.08.006_b0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.08.006_b0260","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0265","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0270","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0275","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0280","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0285","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0290","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0295","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0300","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0305","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.08.006_b0310","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0320","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0325","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jhep.2014.08.006_b0330","doi-asserted-by":"crossref","DOI":"10.2174\/1574887109666140529222602","article-title":"Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection","author":"Gentile","year":"2014","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.jhep.2014.08.006_b0335","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/AAC.02579-13","article-title":"Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection","volume":"58","author":"Sims","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.08.006_b0340","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0350","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/add.12125","article-title":"Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?","volume":"108","author":"de Vos","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2014.08.006_b0355","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/cid\/cit197","article-title":"Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984\u20132011","volume":"57","author":"Witt","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0360","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.gcb.2009.06.011","article-title":"Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men","volume":"33","author":"Cotte","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2014.08.006_b0365","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciu396","article-title":"HIV and HCV infection in the United States: whom and how to test","volume":"59","author":"Panneer","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0370","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.08.006_b0375","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/592171","article-title":"Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe","volume":"198","author":"Soriano","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0380","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.08.006_b0385","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2013.06.028","article-title":"A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection","volume":"59","author":"Beinhardt","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jhep.2013.04.007","article-title":"Treatment optimization and prediction of HCV clearance in patients with acute HCV infection","volume":"59","author":"Mangia","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0395","article-title":"Distinct features in natural history and outcomes of acute hepatitis C","author":"Bunchorntavakul","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2014.08.006_b0400","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/COH.0b013e32834732cd","article-title":"Treatment of acute hepatitis C infection in HIV-infected patients","volume":"6","author":"Boesecke","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jhep.2014.08.006_b0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2009.09.019","article-title":"Effective treatment of injecting drug users with recently acquired hepatitis C virus infection","volume":"138","author":"Dore","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.006_b0410","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2893.2009.01167.x","article-title":"Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis","volume":"17","author":"Corey","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.006_b0415","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0420","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/infdis\/jis213","article-title":"The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design","volume":"205","author":"Vickerman","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0425","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients \u2013 A randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.08.006_b0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/135965350400900108","article-title":"High rate of didanosine-related mitochondrial toxicity in HIV\/HCV-coinfected patients receiving ribavirin","volume":"9","author":"Moreno","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2014.08.006_b0435","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0440","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood.V84.4.1020.1020","article-title":"Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease","volume":"84","author":"Eyster","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2014.08.006_b0445","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.006_b9000","unstructured":"Poizot-Martin I, Bellissant E, Colson P, et al., and the ANRS-HC27 BOCEPREVIH Study Group. ANRS-HC27 Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial. 21st Conference on Retroviruses and Opportunistic Infections, March 3\u20136, 2013; abstract 659LB."},{"key":"10.1016\/j.jhep.2014.08.006_b0545","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0550","unstructured":"Cotte L, Braun J, Vincent C, Sogni P, et al. Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH). 21st Conference on Retroviruses and Opportunistic Infections, March 3\u20136, 2014; abstract 668."},{"key":"10.1016\/j.jhep.2014.08.006_b0465","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0470","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.006_b0555","unstructured":"German P, Pang P, West S, Han L, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 19\u201321 May 2014, Washington, DC; abstract O_06."},{"key":"10.1016\/j.jhep.2014.08.006_b0480","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir","volume":"18","author":"Bifano","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2014.08.006_b0560","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(14)60012-X","article-title":"Safety and efficacy of the all-oral regimen of MK-5172\/MK-8742 +\/\u2212 ribavirin in treatment-na\u00efve, non-cirrhotic, patients with hepatitis C genotype 1 infection: the C-WOTHY study","volume":"60","author":"Herzode","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0490","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3851\/IMP2527","article-title":"Review of drug interactions with telaprevir and antiretrovirals","volume":"18","author":"van Heeswijk","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2014.08.006_b0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkp152","article-title":"Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable","volume":"64","author":"Seden","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2014.08.006_b0500","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1665-2681(19)31022-1","article-title":"A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients","volume":"11","author":"Wilby","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0505","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","article-title":"Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2014.08.006_b0510","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2013.05.020","article-title":"ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection","volume":"59","author":"Asselah","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2014.08.006_b0515","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2013.06.024","article-title":"Direct acting antiviral agents and the path to interferon independence","volume":"12","author":"Schmidt","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.08.006_b0520","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-2652-14-22","article-title":"Hepatitis C in HIV-infected individuals: cure and control, right now","volume":"14","author":"Thomas","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jhep.2014.08.006_b0565","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2893.2006.00749.x","article-title":"Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons","volume":"13","author":"Alvarez","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.006_b0570","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1136\/gut.34.2_Suppl.S107","article-title":"Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis","volume":"34","author":"Visco","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.08.006_b0575","doi-asserted-by":"crossref","first-page":"21509","DOI":"10.1016\/S0021-9258(18)54668-8","article-title":"Mechanism of the potentiating effect of ribavirin on the activity of 2\u2019,3\u2019-dideoxyinosine against human immunodeficiency virus","volume":"266","author":"Balzarini","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.08.006_b0580","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0585","unstructured":"Sovaldi\u2122 (sofosbuvir) tablets prescribing information. Gilead Sciences, Inc., Foster City, CA 2013."},{"key":"10.1016\/j.jhep.2014.08.006_b0590","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/cid\/cis968","article-title":"Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir","volume":"56","author":"Hulskotte","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2014.08.006_b0595","unstructured":"Olysio\u2122 (simeprevir) capsules prescribing information. Janssen Therapeutics, Titusville, NJ 2013."},{"key":"10.1016\/j.jhep.2014.08.006_b0600","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2125.2012.04345.x","article-title":"The Effect of CYP3A Inhibitors and Inducers on the Pharmacokinetics of Telaprevir in Healthy Volunteers","volume":"75","author":"Garg","year":"2013","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814005455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814005455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:52Z","timestamp":1759174372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814005455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0168827814005455"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.08.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of acute and chronic HCV infection in persons with HIV coinfection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}